Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5981504 | 1.00 | HDAC3 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6799798 | 0.90 | MME (0.50) | CYP2C19KIF11CYP1A2MMEACE | |
| SCHEMBL6799795 | 0.90 | MME (0.50) | CYP2C19KIF11CYP1A2MMEACE | |
| SCHEMBL21086847 | 0.87 | HDAC3 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL21086713 | 0.87 | HDAC3 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6670650 | 0.87 | HDAC1 (0.44) | HDAC1MAPTKMT2AKIF11ALDH1A1 | |
| SCHEMBL6670653 | 0.87 | HDAC1 (0.44) | HDAC1MAPTKMT2AKIF11ALDH1A1 | |
| SCHEMBL20732297 | 0.85 | ESR1 (0.42) | KIF11MMEACEALDH1A1 | |
| SCHEMBL5981109 | 0.85 | MAPT (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8715689 | 0.85 | MAPT (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539682-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF TUBULIN INHIBITORS | Wyeth Holdings Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004026814-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF TUBULIN INHIBITORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| US-20040063904-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | claimed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-7626023-B2 | Compounds for treating tumors | WYETH (US) | 2009-12-01 | — | — | US | disclosed |
| US-7626023-B2 | Compounds for treating tumors | WYETH (US) | 2009-12-01 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390910-B2 | Compounds for treating tumors | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390910-B2 | Compounds for treating tumors | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-7078572-B2 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050288486-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION (US) | 2005-12-29 | — | — | US | disclosed |
| US-6951955-B2 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1539682-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF TUBULIN INHIBITORS | Wyeth Holdings Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004047615-A2 | HEMIASTERLIN AFFINITY PROBES AND THEIR USES | WYETH (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004026814-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF TUBULIN INHIBITORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040063904-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | RB1, MRPL9, BCOR | HDAC3 1316/4885HDAC4 1922/4885HDAC1 1196/4885 |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | HDAC3 1392/4885HDAC4 2039/4885HDAC1 1510/4885 |
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | HDAC3 466/4885HDAC4 648/4885HDAC1 265/4885 |
| US-20040063904-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | TUBB1, TUBA1C, TUBB | HDAC3 1941/4885HDAC4 1568/4885HDAC1 1114/4885 |
| US-20050288486-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | TUBB1, TUBB, TUBA1C | HDAC3 1652/4885HDAC4 1694/4885HDAC1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.